Report cover image

Sleep Apnea: Market View

Publisher GlobalData
Published Jun 23, 2025
Length 88 Pages
SKU # GBDT20204579

Description

Sleep Apnea: Market View

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Sleep Apnea Therapeutics.

In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of sleep apnea, representing a large portion of global cases.

Currently, the sleep apnea market is saturated with generic drugs, and the sodium-dependent dopamine transporter (DAT) drug class dominates the approved innovator drugs landscape.

The sleep apnea pipeline holds 27 molecules, with one asset in the pre-registration stage, five assets in Phase III development, and another 12 in Phase II.

Over the past decade, 336 clinical trials have been conducted in sleep apnea. The year with the most studies initiated was 2022, with 41 trials, followed by 2023 with 38 trials.

During the past 18 months, approximately six mergers and acquisitions and three strategic alliances involving companies developing sleep apnea assets were completed globally.

Scope

GlobalData’s Sleep Apnea: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Sleep Apnea Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Sleep Apnea Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

88 Pages
  • Report Scope
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of Sleep Apnea in 2024 and 2029
  • Treatment Overview
    • Marketed Drugs - Leading Marketed Drugs in Sleep Apnea
    • Marketed Drugs - Overview of Drugs by Approval and Drug Type
    • Marketed Drugs - Overview by MOA
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile - SK Biopharmaceuticals' Sunosi
    • Marketed Drug Profile - Teva Pharmaceutical's Nuvigil
    • Marketed Drug Profile - Teva Pharmaceutical's Provigil/Alertec/Modafinil/ Modafinil Par/Modasomil/Modavigil/Modiodal
    • Marketed Drug Profile - Eli Lilly's Zepbound
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Modiodal
    • Marketed Drugs - Time to Pricing and Reimbursement for Nuvigil
    • Marketed Drugs - Time to Pricing and Reimbursement for Sunosi
    • Pipeline Drugs Overview - Mid- to Late-Stage Pipeline Drugs in Sleep Apnea
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by MOA
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drug Profile - Bioprojet's Pitolisant Hydrochloride: Sales Forecast
    • Pipeline Drug Profile - Eli Lilly's Retatrutide: Sales Forecast
    • Pipeline Drug Profile - Eli Lilly's Retatrutide: Summary
    • Pipeline Drug Profile - Eli Lilly's Orforglipron Calcium: Sales Forecast
    • Pipeline Drug Profile - Eli Lilly's Orforglipron Calcium: Summary
    • Pipeline Drug Profile - Apnimed's AD-109: Sales Forecast
    • Pipeline Drug Profile - Apnimed's AD-109: Summary
    • Pipeline Drug Profile - Incannex Healthcare's Acetazolamide + Dronabinol
    • Pipeline Drug Profile - Incannex Healthcare's Acetazolamide + Dronabinol: Summary
    • Pipeline Drugs - PTSR and LoA in Respiratory Disorders & Sleep Apnea
    • Pipeline Drugs - PTSR and LoA in Sleep Apnea
    • Clinical Trials in Sleep Apnea - Historical Overview by Phase
    • Clinical Trials in Sleep Apnea - Historical Overview by Sponsor Type
    • Clinical Trials in Sleep Apnea - Overview by Phase
    • Clinical Trials in Sleep Apnea - Overview by Status
    • Clinical Trials in Sleep Apnea - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in Sleep Apnea - Trials with a Virtual Component
    • Clinical Trials in Sleep Apnea - Top 20 Biomarkers by Trial Phase
    • Clinical Trials in Sleep Apnea - Geographic Overview
    • Clinical Trials in Sleep Apnea - Single-Country and Multinational Trials by Region
    • Clinical Trials in Sleep Apnea - Top Sponsors with Breakdown by Phase
    • Clinical Trials in Sleep Apnea - Top Sponsors with Breakdown by Status
    • Clinical Trials in Sleep Apnea - Overview by Endpoint Status
    • Clinical Trials in Sleep Apnea - Overview by Race and Ethnicity of Trial Participants
    • Clinical Trials in Sleep Apnea - Enrollment Data
    • Clinical Trials in Sleep Apnea - Overview of Sites by Geography
    • Clinical Trials in Sleep Apnea - Top 20 Countries for Trial Sites
    • Clinical Trials in Sleep Apnea - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for Sleep Apnea
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in Sleep Apnea by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in Sleep Apnea
    • Commercial Assessment - Key Market Players in Sleep Apnea
    • Future Market Catalysts - Upcoming Market Catalysts in Sleep Apnea
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us